Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

177Lu-PSMA-617

- PMLiVE

CV data sets up Novartis’ Ilaris for blockbuster sales

Drug shown to reduce major adverse cardiovascular events

- PMLiVE

Sandoz joins Europe’s MabThera biosimilar push

Novartis’ unit is second company to claim approval in Europe for biosimilar version

EU flag

Medicxi aims to plug funding gap for European biotech

Fund also backed by Novartis, Alphabet’s Verily unit and the EIF

Google’s Verily backs $300m European life sciences fund

The Medicxi fund for drug development firms also attracts support from Novartis

- PMLiVE

Pfizer hits accelerator on Xtandi trial in early prostate cancer

US pharma giant expects PROSPER trial results later this year

Novartis tie-up with IBM Watson Health in breast cancer

Will combine real-world patient data and cognitive computing

- PMLiVE

Practice-changing data for J&J’s Zytiga in prostate cancer

LATITUDE study shows combined drug therapy reduces death risk by 38%

Novartis building

Novartis’ Zykadia claims US approval for first-line lung cancer

The Swiss pharma giant’s drug also receives CHMP positive opinion

Novartis building

Novartis’ Zykadia prepped to take on Xalkori in Europe

The Swiss pharma giant’s drug will treat ALK-positive NSCLC patients

Novartis day

Novartis’ Swiss head of operations reveals job cuts

Leuenberger suggests cuts are needed to maintain competiveness

- PMLiVE

J&J aiming for above-average growth thanks to stream of blockbusters

US firm enters highly productive R&D phase

- PMLiVE

Novartis’ Rydapt approval ends long AML therapy drought

Targeted blood cancer drug wins US licence from the FDA

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links